Want to see CUE full AI Analyst Report?
Cue Biopharma (CUE) AI Stock Analysis
Cue Biopharma
(NASDAQ:CUE)
The overall score is heavily pressured by severe financial distress, including widening losses and a near-zero equity base, and a bearish technical trend. These risks are partially offset by promising clinical data for CUE-221 and a strategic CFO hire, which provide a potential catalyst for future value creation if the company can secure necessary funding.
Cue Biopharma (CUE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $151.61M
- Dividend Yield
- ―
- Average Volume (3M)
- 260.54K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 3.20
- Revenue Growth
- 354.37%
- EPS Growth
- -63.33%
- Country
- US
- Employees
- 29
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Cue Biopharma Business Overview & Revenue Model
Company Description
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various ca...
How the Company Makes Money
Cue Biopharma has historically generated little to no recurring product revenue because it is a clinical-stage company without approved commercial therapies. As a result, its cash inflows have primarily come from (1) collaboration and partnership arr...
Cue Biopharma Earnings Call Summary
The call presented several positive developments in clinical trials and strategic financial management, but also noted delays in trial launches and competitive market challenges.
Q2-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During Cue Biopharma's Q2 2024 earnings call, the executives provided guidance on several metrics and strategic priorities. They highlighted their focus on reducing capital requirements by achieving a cash burn reduction from $40 million to $30 million annually, extending their runway to mid-2025. The company is advancing its CUE-101 and CUE-102 oncology programs, with CUE-101 showing an objective response rate of 46% and a notable 12-month overall survival rate of 90% in a combination trial with pembrolizumab. Cue-401, in collaboration with ONO Pharmaceuticals, targets autoimmune diseases, with lead candidate selection anticipated in Q1 2025. Additionally, CUE-501 is being positioned for strategic partnering, aimed at addressing B-cell-mediated autoimmune diseases. The company's approach includes leveraging strategic partnerships to optimize resource allocation and bolster cash flow through milestone payments and potential co-development agreements.
Cue Biopharma Financial Statement Overview
Summary
Revenue growth of 15% and near-100% gross margins are strong positives, but are overshadowed by a -435% net margin, widening losses, critically low equity of $2.3M, and a high cash burn rate. The high debt-to-equity ratio of 1.33 and reliance on external financing indicate severe financial distress.
Income Statement
18Very NegativeBalance Sheet
10Very NegativeCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 37.65M | 27.47M | 9.29M | 5.49M | 1.25M | 14.94M |
| Gross Profit | 37.54M | 27.47M | 9.29M | -32.61M | 1.25M | 16.72M |
| EBITDA | -95.74M | -24.79M | -37.53M | -46.05M | -50.49M | -45.44M |
| Net Income | -164.11M | -26.60M | -40.67M | -50.73M | -53.01M | -44.16M |
Balance Sheet | ||||||
| Total Assets | 30.71M | 42.21M | 32.19M | 61.53M | 91.28M | 83.40M |
| Cash, Cash Equivalents and Short-Term Investments | 17.39M | 27.14M | 22.46M | 48.51M | 76.29M | 64.37M |
| Total Debt | 8.81M | 4.20M | 8.88M | 14.70M | 19.32M | 12.02M |
| Total Liabilities | 28.40M | 15.78M | 14.69M | 24.45M | 25.60M | 17.91M |
| Stockholders Equity | 2.31M | 26.43M | 17.50M | 37.09M | 65.68M | 65.49M |
Cash Flow | ||||||
| Free Cash Flow | -50.17M | -21.86M | -36.40M | -39.96M | -41.98M | -39.75M |
| Operating Cash Flow | -50.05M | -21.69M | -36.33M | -39.96M | -41.81M | -38.84M |
| Investing Cash Flow | 131.00K | 75.00K | 32.00K | 25.00M | -24.61M | 9.11M |
| Financing Cash Flow | 39.82M | 26.29M | 10.24M | 11.86M | 53.66M | 19.23M |
Cue Biopharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUE, the sentiment is Neutral. The current price of 20.87 is above the 20-day moving average (MA) of 20.40, below the 50-day MA of 25.52, and below the 200-day MA of 21.15, indicating a neutral trend. The MACD of -1.77 indicates Negative momentum. The RSI at 46.69 is Neutral, neither overbought nor oversold. The STOCH value of 82.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CUE.
Cue Biopharma Risk Analysis
Cue Biopharma disclosed 65 risk factors in its most recent earnings report. Cue Biopharma reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
1 New RiskCue Biopharma Peers Comparison
Overall Rating
- CUE48Neutral
ACRV45Neutral
CELU44Neutral
MAIA44Neutral
ALGS39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CUE | 48Neutral | $151.61M | -0.77 | -1032.19% | ― | 354.37% | -63.33% |
| ACRV | 45Neutral | $71.14M | -0.88 | -70.14% | ― | ― | 16.04% |
| CELU | 44Neutral | $25.96M | -0.45 | 142.25% | ― | -58.14% | 47.25% |
| MAIA | 44Neutral | $67.92M | -1.74 | -211.15% | ― | ― | -7.28% |
| ALGS | 39Underperform | $29.97M | -0.66 | -160.72% | ― | 893.01% | 41.74% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CUE | Cue Biopharma | 20.87 | -0.65 | -3.04% | |
| CELU | Celularity Inc. | 0.80 | -0.92 | -53.49% | |
| ALGS | Aligos Therapeutics, Inc. | 4.80 | -2.73 | -36.25% | |
| GNTA | Genenta Science SpA Sponsored ADR | 0.62 | -1.94 | -75.86% | |
| MAIA | MAIA Biotechnology, Inc. | 1.10 | -0.06 | -5.17% | |
| ACRV | Acrivon Therapeutics, Inc. | 1.66 | -0.67 | -28.76% |
Cue Biopharma Corporate Events
Cue Biopharma reports positive Phase 2 CUE-221 data
PositiveOn September 20, 2026, Cue Biopharma reported positive topline data from a Phase 2 trial of CUE-221 in moderate to severe chronic spontaneous urticaria conducted in China with 145 patients whose disease was inadequately controlled on H1 antihistamine...
Cue Biopharma Appoints Veteran James Ahlers as CFO
PositiveCue Biopharma, Inc. announced on August 3, 2026, that its board appointed veteran life sciences finance executive James Ahlers as chief financial officer and principal financial officer, effective July 30, 2026, underscoring the company’s focus...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026